Published in Gut on June 01, 2010
New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25
Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci (2012) 1.09
Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci (2011) 1.01
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol (2014) 0.97
Central muscarinic cholinergic activation alters interaction between splenic dendritic cell and CD4+CD25- T cells in experimental colitis. PLoS One (2014) 0.83
Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol (2015) 0.81
Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96. J Immunol (2016) 0.77
Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One (2014) 0.77
CPSI-121 pharmacologically prevents intestinal barrier dysfunction after cutaneous burn through a vagus nerve-dependent mechanism. J Trauma Acute Care Surg (2012) 0.76
The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation. PLoS One (2015) 0.75
The multi-target effects of CNI-1493: convergence of anti-amylodogenic and anti-inflammatory properties in animal models of Alzheimer's disease. Mol Med (2016) 0.75
New molecular targets for the treatment of sarcoidosis. Curr Opin Pulm Med (2016) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet (2006) 4.72
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 4.20
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A (2009) 4.02
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96
On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet (2008) 3.95
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Nod2 is essential for temporal development of intestinal microbial communities. Gut (2011) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med (2004) 3.63
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet (2010) 3.39
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology (2007) 3.37
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest (2005) 3.36
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25